Antiplatelet Therapy
20
2
2
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
10.0%
2 terminated out of 20 trials
77.8%
-8.7% vs benchmark
30%
6 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (20)
Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment
Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI
T-TAS® wS Method Comparison
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
DACAB Trial: Follow-up Extension
MCE Identifying Bleeding Lesions in Patients with Antiplatelet Drugs-Related Acute Non-Hematochezia Gastrointestinal Bleeding
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG
Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study
The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI
Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor
LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)
Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey
Platelet Reactivity And Clinical ThrombotIC Events Study
Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury
Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome
Platelet Inhibition in the Acute Phase of STEMI
Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study
REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)